Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development

Core Viewpoint - Karolinska Development AB's portfolio company SVF Vaccines has signed a non-binding letter of intent for a reverse takeover with Novakand Pharma AB, aiming for SVF Vaccines to be listed on Nasdaq First North Premier [1][8]. Group 1: Transaction Details - The reverse takeover is subject to a final agreement and approval at Novakand's extraordinary general meeting, which will result in SVF Vaccines shareholders owning approximately 67% of the new entity, renamed SVF Vaccines Holding AB [3][8]. - The transaction will provide SVF Vaccines access to Novakand's existing cash balance, enhancing its financial position [3]. Group 2: Development Plans - SVF Vaccines plans to conduct a capital raise primarily to finance the development of its lead program, SVF-001, targeting hepatitis B and D [4]. - The next step involves initiating a Phase 1 clinical study to demonstrate the generation of functional human antibodies and T cells against HDV, expected to be completed approximately 24 months post-transaction [4]. Group 3: Research and Validation - Recent preclinical results indicate that SVF-001 has a clear antiviral effect against HDV in a humanized mouse model for up to six weeks post-treatment, suggesting a long-lasting effect [5]. - The company has developed its platform efficiently, partly through grants, while delivering validating research data and a solid future development plan [7].